logo-loader

Creso Pharma benefits from medicinal cannabis uptake in Israel

Last updated: 19:30 13 Oct 2020 EDT, First published: 19:25 13 Oct 2020 EDT

Creso Pharma Ltd - Creso Pharma continues to benefit from medicinal cannabis uptake in Israel
Israel is now the world’s biggest importer of medicinal cannabis flower

Creso Pharma Ltd (ASX:CPH) welcomes recent Israeli Medical Cannabis Agency (IMCA) data that highlights a significant recent increase in medicinal cannabis uptake from patients in the country.

The data from IMCA, which is part of Israel’s Ministry of Health, shows that the number of authorised medicinal cannabis patients in the country has more than doubled over the past two years to in excess of 70,000 per month.

Notably, medicinal cannabis flower is the most common form of cannabis prescribed followed by extracts and oils.

“Rapidly growing market”

Israel is now the world’s biggest importer of medicinal cannabis flower and the rapidly growing Israeli market provides an exciting opportunity for Creso Pharma to leverage existing in-country relationships to accelerate growth.

Creso Pharma non-executive director and head of technology, innovation and distribution Miri Halperin Wernli said: “The data coming out of the IMCA is tremendously encouraging and highlights the considerable potential that Creso Pharma has in this rapidly growing market.

“Israel is widely recognised as one of the most active and more progressive cannabis markets globally and the company is very confident it can continue to build on its existing partnership with Univo as it looks to capture a larger market position.

“Management is continuing to progress a number of business development initiatives in Israel and has several value catalysts on the horizon.”

Focused on further expansion

Israel is an important market for Creso Pharma and the company is confident that it can continue to benefit from the rapid uptake of medicinal cannabis amongst Israeli patients.

The company entered the Israeli market in April 2020, following the receipt of a C$775,000 purchase order from one of Israel’s leading medicinal cannabis company’s Univo Pharmaceuticals Ltd (TLV:UNVO) through wholly-owned subsidiary Mernova Medicinal Inc.

Creso has since received a second purchase order from Univo for its premium, cured and hand-trimmed dried medicinal cannabis flower, valued at US$625,690.

Further expansion into Israel remains a strong focal point and the company will continue to monitor the evolving legislative environment, as it progresses several business development initiatives to accelerate growth into this market.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

26 minutes ago